We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
(+81%)
Cap. Flow
+$45.1M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$40.8M |
| 2 |
United Therapeutics
UTHR
|
+$26.2M |
| 3 |
HSKA
Heska Corp
HSKA
|
+$20M |
| 4 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$18.2M |
| 5 |
AstraZeneca
AZN
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ChemoCentryx, Inc.
CCXI
|
+$29.3M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$27.8M |
| 3 |
Danaher
DHR
|
+$20.4M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.4M |
| 5 |
GSK
GSK
|
+$11.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.4% |
| 2 | Miscellaneous | 16.98% |
| 3 | Communication Services | 1.62% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
DELISTED
scPharmaceuticals
SCPH
| $1.82M | 0.25% |
247,419
+115,000
| +87% | +$1.01M |
2019 Q2
4 quarters
|
|
52
Prothena Corp
PRTA
$432M
| $1.59M | 0.22% |
+152,213
| New | +$1.69M |
2020 Q2
0 quarters
|
|
53
Community Health Systems
CYH
$406M
| $1.48M | 0.2% |
492,272
-88,078
| -15% | -$283K |
2019 Q3
3 quarters
|
|
|
KRSA
54
Korsana Biosciences, Inc. Common Stock
KRSA
$1.47B
| $1.46M | 0.2% |
1,769
-639
| -27% | -$374K |
2020 Q1
1 quarter
|
|
55
Zymeworks
ZYME
$1.81B
| $1.44M | 0.2% |
+40,000
| New | +$1.47M |
2020 Q2
0 quarters
|
|
56
DELISTED
Carisma Therapeutics
CARM
| $1.44M | 0.2% |
100,000
+35,000
| +54% | +$472K |
2019 Q4
2 quarters
|
|
57
Protara Therapeutics
TARA
$138M
| $1.36M | 0.19% |
46,310
+13,832
| +43% | +$428K |
2020 Q1
1 quarter
|
|
58
DELISTED
Xoma
XOMA
| $1.27M | 0.17% |
+64,056
| New | +$1.41M |
2020 Q2
0 quarters
|
|
59
Solid Biosciences
SLDB
$589M
| $1.19M | 0.16% |
+27,135
| New | +$1.13M |
2020 Q2
0 quarters
|
|
60
DELISTED
KalVista Pharmaceuticals
KALV
| $1.09M | 0.15% |
+89,806
| New | +$955K |
2020 Q2
0 quarters
|
|
61
uniQure
QURE
$1.51B
| $1.03M | 0.14% |
+22,928
| New | +$1.35M |
2020 Q2
0 quarters
|
|
62
DELISTED
Dynavax Technologies
DVAX
| $867K | 0.12% |
+97,800
| New | +$494K |
2020 Q2
0 quarters
|
|
|
TLGT
63
DELISTED
Teligent, Inc
TLGT
| $859K | 0.12% |
354,998
-31,292
| -8% | -$110K |
2017 Q4
10 quarters
|
|
64
Burning Rock Biotech
BNR
$134M
| $810K | 0.11% |
+3,000
| New | +$822K |
2020 Q2
0 quarters
|
|
65
PUT
DELISTED
Air Lease Corp
AL
| $586K | 0.08% |
20,000
| – | – |
2020 Q1
1 quarter
|
|
|
RVLP
66
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $532K | 0.07% |
+79,037
| New | +$387K |
2020 Q2
0 quarters
|
|
|
EIGR
67
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $470K | 0.06% |
1,634
-690
| -30% | -$203K |
2019 Q1
5 quarters
|
|
68
Immunovant
IMVT
$5.52B
| $299K | 0.04% |
12,266
-64,600
| -84% | -$1.38M |
2019 Q4
2 quarters
|
|
|
ZGNX
69
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $149K | 0.02% |
5,500
| – | – |
2020 Q1
1 quarter
|
|
70
PUT
Amarin Corp
AMRN
$240M
| – | – |
-7,500
| Closed | -$600K | – |
|
71
Aquestive Therapeutics
AQST
$473M
| – | – |
-300,000
| Closed | -$657K | – |
|
72
eHealth
EHTH
$18.5M
| – | – |
-3,153
| Closed | -$444K | – |
|
73
InflaRx
IFRX
$193M
| – | – |
-195,488
| Closed | -$747K | – |
|
74
DELISTED
IGM Biosciences
IGMS
| – | – |
-9,770
| Closed | -$549K | – |
|
75
Iovance Biotherapeutics
IOVA
$6.13B
| – | – |
-90,047
| Closed | -$2.7M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.
- Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
- Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
- Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
- Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
- Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
- Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
- Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.
Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.